Welcome to our dedicated page for Henry Schein news (Ticker: HSIC), a resource for investors and traders seeking the latest updates and insights on Henry Schein stock.
Henry Schein, Inc. (NASDAQ: HSIC) generates a steady flow of news as a FORTUNE 500 and S&P 500® health care solutions company serving office-based dental and medical practitioners. As a medical, dental, and hospital equipment and supplies merchant wholesaler with a significant technology footprint, the company issues updates that cover financial performance, leadership changes, partnerships, and product and technology developments.
Investors following HSIC news will find regular earnings and guidance announcements, including quarterly financial results and updates on sales growth across its Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology segments. These releases often highlight trends in dental and medical distribution, specialty dental products, and technology adoption, as well as commentary on strategic initiatives such as the company’s BOLD+1 strategy and value creation programs.
Henry Schein news also includes leadership and governance updates, such as the announced retirement of long-time CEO Stanley M. Bergman from the chief executive role and the appointment of Frederick M. Lowery as the company’s next CEO, effective March 2, 2026. These items provide insight into succession planning and the company’s approach to long-term leadership continuity.
Another key theme in HSIC coverage is technology and innovation in dental practice management. Through Henry Schein One, the company reports on new AI-enabled workflows, embedded automation, and collaborations with partners like Amazon Web Services and VideaHealth. News items describe developments in practice management platforms such as Dentrix and Dentrix Ascend, including AI-driven documentation, imaging, and revenue cycle tools.
In addition, Henry Schein announces strategic partnerships and distribution agreements, such as its expanded relationship with vVARDIS for the Curodont Repair Fluoride Plus product across U.S. dental segments. These stories shed light on how the company broadens its product offerings and supports dental professionals with new clinical options.
For investors, analysts, and health care professionals, the HSIC news feed on Stock Titan offers a centralized view of these corporate developments, helping users monitor how Henry Schein’s distribution, specialty products, and technology initiatives evolve over time.
BioHorizons has introduced the Tapered Pro Conical, a dental implant featuring a deep conical connection designed to enhance surgical efficiency and provide immediate treatment options. This product is part of Henry Schein's broader strategy to invest in innovative technologies for clinical and workflow improvements. The Tapered Pro Conical incorporates the patented CONELOG® connection and Laser-Lok microchannels, which aid in connective tissue attachment and crestal bone retention. It is optimized for primary stability and includes self-tapping helical cutting flutes for controlled implant placement. The accompanying surgical kit supports both free hand and keyless guided approaches, enhancing surgical and restorative efficiency with just two prosthetic platforms.
The S.M.I.L.E. Healthcare Pathway Program, led by Henry Schein (NASDAQ: HSIC), the National Dental Association, and the Schattner Foundation, announced new partnerships to enhance its mission. Organizations joining include the Hispanic Dental Association, the Society of American Indian Dentists, Meharry Medical College School of Dentistry, and A.T. Still University's dental schools. The program aims to recruit students from underrepresented backgrounds into the dental profession through mentorship, hands-on learning, and career exposure. The 2024 session will occur from July 7-12 in Nashville, Tennessee.
Henry Schein (Nasdaq: HSIC), the global leader in healthcare solutions for dental and medical practitioners, announced its upcoming presentations at key investor conferences in June 2024. The company will present at the Jefferies Global Healthcare Conference in New York on June 5 at 10:00 a.m. Eastern time and the Goldman Sachs Global Healthcare Conference in Miami on June 11 at 11:20 a.m. Eastern time.
These presentations will be accessible via live webcast, with replays available post-event on the Henry Schein website.
Henry Schein (Nasdaq: HSIC) commits over $200,000 in cash and healthcare product donations to support recovery efforts in Brazil after severe flooding. Both the company and the Henry Schein Cares Foundation (HSCF) will match employee contributions to the 2024 Relief Fund, which aims to help those affected by the disaster. The initiative includes donations of essential healthcare supplies to partner relief organizations. Henry Schein's engagement with Brazil's dental sector since 2014 involves companies like Dental Cremer, Simples Dental, and S.I.N. Implant System. Customers impacted by the floods can seek assistance through local customer service channels.
Henry Schein, Inc. extends its partnership with Special Olympics through 2025, supporting health screenings and education for athletes with intellectual disabilities worldwide. The company donates oral health and medical care products for the Healthy Athletes program at select events across five countries. This collaboration aims to promote the physical and social-emotional well-being of individuals with intellectual disabilities, reducing health disparities and increasing life expectancy. Henry Schein's contributions have benefitted Special Olympics athletes since 2018, with recent support during the June 2023 Special Olympics World Games in Berlin, Germany. The partnership encourages health care providers to volunteer their services and enhance care practices for individuals with intellectual disabilities.
Henry Schein, Inc. reported solid first-quarter 2024 financial results with sales growth of 3.7%, GAAP diluted EPS of $0.72, and non-GAAP diluted EPS of $1.10. The company tightened its total sales growth guidance range to 8% to 10% and affirmed its 2024 non-GAAP diluted EPS guidance of $5.00 to $5.16. Adjusted EBITDA growth is expected to be more than 15% in 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Henry Schein (HSIC)?
What is the market cap of Henry Schein (HSIC)?
